|
|||||
|
|
Atopic dermatitis-like graft-versus-host disease treated with dupilumab |
|
| Authors: | Mary Larijani MD Diana Zarowin BS Anne Wohlschlaeger MSN CRNP Marissa J. Perman MD James R. Treat MD |
| Affiliation: | 1. The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA;2. Albert Einstein College of Medicine, Bronx, New York, USA;3. Blood and Marrow Transplant Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA;4. The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA Section of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA |
| Abstract: | The mainstay of treatment for atopic dermatitis (AD)-like graft-versus-host disease (GVHD) in both pediatric and adult patients includes oral corticosteroids with or without other systemic immunosuppressive therapies. To our knowledge, we report the first case series of dupilumab in the treatment of AD-like GVHD in a pediatric cohort of four patients, where we observed clinical improvement of GVHD as well as a reduction in itch in 3/4 (75%) patients. Our findings suggest that dupilumab is not only effective in treating AD-like GVHD, but also reduces systemic immunosuppression in the pediatric transplant population. The ability to reduce the length and amount of immunosuppression as well as improve quality of life suggest that dupilumab may serve as a safe and effective therapeutic option in our transplant population with GVHD. |
| Keywords: | atopic dermatitis skin signs of systemic disease therapy-systemic |